Antimicrobial Strategies Against Drug-Resistant Bacteria

The global escalation of antibiotic resistance has driven the development of multifaceted interventions to outpace evolving pathogens. Strategies now encompass the discovery of novel chemical scaffolds, repurposing of established drugs, and the deployment of adjuvant therapies that restore the efficacy of conventional antibiotics. Researchers are targeting fundamental bacterial processes—cell wall biosynthesis, energy transduction, stress‐response pathways and persistence mechanisms—while also disrupting protective communities such as biofilms. Natural products, membrane‐active agents and host‐directed approaches are being integrated with insights into microbial physiology and host–pathogen interactions to yield more robust and enduring treatments.

Research from Nature Portfolio

In an innovative example of drug repurposing, an anthelmintic compound has been shown to eradicate a gastric pathogen by collapsing its proton motive force. The molecule remains stable under acidic conditions, synergises with proton pump inhibitors, and does not induce resistance over extended exposure in vitro. Efficacy in animal infection models further underlines the promise of repositioned therapeutics to overcome traditional resistance mechanisms.

Antimicrobial Strategies Against Drug-Resistant Bacteria publication trend

The graph below shows the total number of articles in antimicrobial strategies against drug-resistant bacteria across all publications each year (not limited to Nature Index journals).

Technical terms

Antibiotic resistance: The ability of bacteria to survive and multiply despite exposure to one or more antimicrobial agents.

Proton motive force: The electrochemical gradient across the bacterial membrane that drives ATP synthesis and other energy‐dependent processes.

Biofilm: A structured community of microorganisms embedded in a self‐produced extracellular matrix, which enhances protection from antibiotics and host defences.

Drug repurposing: The application of existing, approved drugs to new therapeutic indications, accelerating development timelines.

Adjuvant therapy: The use of one agent in combination with another to enhance antimicrobial efficacy and counteract resistance.

References

1. Celastrol Combats Methicillin‐Resistant Staphylococcus aureus by Targeting Δ1‐Pyrroline‐5‐Carboxylate Dehydrogenase. Advanced Science (2023).
2. Novel antibiotics against Staphylococcus aureus without detectable resistance by targeting proton motive force and FtsH. MedComm (2025).
3. Repurposing the anthelmintic drug niclosamide to combat Helicobacter pylori. Scientific Reports (2018).
4. Diclofenac Resensitizes Methicillin‐Resistant Staphylococcus aureus to β‐Lactams and Prevents Implant Infections. Advanced Science (2021).